本帖最后由 老马 于 2012-1-13 21:20 编辑 ; k9 r" Q1 a* X# s2 s
# m9 ~. h: m/ z$ w; I
爱必妥和阿瓦斯丁的比较2 X* _2 P+ {) G+ n: j; Z
) a4 X' G/ Z* f4 P$ z: N( [
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/* j% g6 O* X0 s% }( [
7 k6 m7 v; l1 E8 c
d2 v4 N4 `, m# b* j
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/5 v, K2 W; F9 R- o" I u9 L" H. r
==================================================6 W* k, r( v% j( C0 L6 l3 E( ^
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ w) O1 O5 \+ N& {. K5 T( UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. F9 E1 P$ N: z% f; e; m4 B: lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' u$ S1 `% A* o: M3 Y S" Q
|